Acquired by PMC International in December of 2017, PMC Isochem is a world leader in custom pharmaceutical manufacturing. We are a fully integrated business comprised of research, product/process development, regulatory approvals, pilot scale and full plant-scale production of drug intermediates and active pharma ingredients (APIs) for major pharmaceutical companies worldwide to serve the needs of Oncology, Cardiovascular, Infectious, Gastro-Intestinal, Neurology and rare diseases. These facilities, with a combined footprint of over 40 acres, are located at three sites -- Gennevilliers, Pithiviers, and Vert-Le-Petit -- within a 60 miles radius of Paris. The facilities are all cGMP US-FDA audited plants for manufacturing pharmaceutical products.
As a leading contract drug development and manufacturing organization (CDMO), we are masters of complex processes and can manufacture products to the most stringent pharmaceutical regulatory standards. We serve a broad range of customers in many application fields, from leading global companies to virtual and emerging organizations. PMC Isochem offers services in three pharma-related fields: custom synthesis, high technology manufacturing in multi-step chemical synthesis and direct supply of more than 2,300 specific compounds and products, including regulated and non-regulated intermediates and active ingredients. Technical strengths include high-pressure chemistry, low-temperature chemistry, hazardous chemistry, and peptide chemistry. We are continually expanding our technology platform and service offerings to meet customer demand.
For more information, please visit the PMC Isochem site by clicking here or contact us directly at email@example.com